SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Amneal Pharmaceuticals, Inc. (AMRX) News

Follow Amneal Pharmaceuticals, Inc. (AMRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AMRX Asset equity Sector Markets 90 days 16 Last 21.37 Updated Nov 03, 2026, 02:32 PM UTC Open live news feed Open AMRX chart & news
M Amneal Pharmaceuticals Reports Quarterly Results Through September 30 EQUITY | Nov 03, 2026, 02:32 PM UTC M Amneal Reports Q3 2026 Results and Raises Full-Year Guidance Amneal reported third-quarter revenue of $863 million, up 10% year over year; adjusted EBITDA rose 30% to $207 million and adjusted diluted EPS increased 53% to $0.26. It raised full-year 2026 guidance for revenue, adjus EQUITY | Nov 03, 2026, 12:33 PM UTC M Amneal Pharmaceuticals Q3 Adjusted Earnings and Revenue Rise Amneal Pharmaceuticals reported rises in adjusted earnings and revenue for Q3. EQUITY | Nov 03, 2026, 11:36 AM UTC M Amneal Pharmaceuticals Raises FY26 Revenue View to $3.15B–$3.25B EARNINGS | Nov 03, 2026, 11:15 AM UTC M Amneal Expects 2026 Adjusted EPS of $1.04–$1.08 Amneal Pharmaceuticals expects 2026 adjusted EPS of $1.04–$1.08, versus a FactSet estimate of $1.03. EARNINGS | Nov 03, 2026, 11:14 AM UTC M Amneal Pharmaceuticals Reports Third-Quarter Revenue of $862.7M EQUITY | Nov 03, 2026, 11:14 AM UTC M Amneal Reports Q3 2026 Revenue of $863 Million, Updates Guidance Amneal reported a GAAP net loss of $22 million and a diluted loss per share of $(0.06). Adjusted EBITDA was $207 million, with adjusted diluted EPS of $0.26. EQUITY | Nov 03, 2026, 11:12 AM UTC M Amneal Reports Third-Quarter 2026 Financial Results EQUITY | Nov 03, 2026, 11:03 AM UTC M Amneal Q3 Adjusted EPS USD 0.26 vs. IBES Estimate USD 0.23 EARNINGS | Nov 03, 2026, 11:03 AM UTC M US Estrogen Shortage Worsens as Demand Shifts to Alternatives Pharmacies report supply problems with estrogen injections and vaginal creams. Viatris has added shifts at its Vermont plant and plans an additional production line to meet demand. EQUITY | Oct 28, 2026, 10:05 AM UTC M Amneal Pharmaceuticals Q3 Revenue Estimate and EPS Forecast Amneal Pharmaceuticals is expected to report Q3'26 results before the market opens on November 3. Revenue and EPS estimates were provided. EQUITY | Oct 27, 2026, 11:02 AM UTC M Amneal to report Q3 2026 results on Nov. 3, 2026 EQUITY | Oct 08, 2026, 12:01 PM UTC L Amneal Pharmaceuticals Price Target Announced at $27.00/Share by Oppenheimer Ratings actions from Benzinga: GMT) Amneal Pharmaceuticals Initiated at Outperform by OppenheimerRatings actions from Benzinga NEWS | Sep 23, 2026, 12:20 PM UTC M Ipsen shares drop after FDA approval of U.S. generic rival Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected. EQUITY | Sep 21, 2026, 10:02 AM UTC L AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection REGULATION | Sep 18, 2026, 08:01 PM UTC L Leerink Partners sets $23.00 share price target for Amneal Pharmaceuticals Leerink Partners announced a $23.00 per-share price target for Amneal Pharmaceuticals, according to ratings actions cited by Benzinga. EQUITY | Sep 09, 2026, 03:12 PM UTC H Amneal Completes Acquisition of Kashiv BioSciences Amneal acquires Kashiv BioSciences MNA | Aug 10, 2026, 12:01 PM UTC L AMRX -6% after Q2 results AMRX -6% after Q2 results EARNINGS | Jul 30, 2026, 01:34 PM UTC H earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee EARNINGS | Jul 30, 2026, 11:18 AM UTC L AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M AMRX Amneal Pharmaceuticals RESULTS: Q2, Q2 Net Income $58M, Q2 ADJ EPS $0.3 vs. EST $0.22, Q2 REV $796M, Q2 ADJ EBITDA $206M EARNINGS | Jul 30, 2026, 10:02 AM UTC L Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050 Amneal Pharmaceuticals (NASDAQ: AMRX ) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200 bil EARNINGS | Jul 30, 2026, 10:01 AM UTC L AMRX - Amneal Reports Second Quarter 2026 Financial Results AMRX - Amneal Reports Second Quarter 2026 Financial Results EARNINGS | Jul 30, 2026, 10:00 AM UTC L AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO EQUITY | Jul 22, 2026, 12:51 PM UTC L AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch n AMRX Amneal expands iohexol injection portfolio with U.S. FDA approval of additional strengths and presentations Amneal Pharma - to launch new iohexol injection products in Q3 2026 REGULATION | Jul 17, 2026, 12:00 PM UTC H Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc MACRO | Jun 30, 2026, 02:17 PM UTC L US FDA selects seven participants for precheck pilot program to advance US drug manufacturing Names include Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin and Regeneron REGULATION | Jun 29, 2026, 08:34 PM UTC